Avalo Therapeutics
AVTX
18 hedge funds and large institutions have $18.4M invested in Avalo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 26 closing their positions.
68% more capital invested
Capital invested by funds: $10.9M → $18.4M (+$7.48M)
0.22% more ownership
Funds ownership: 0.02% → 0.25% (+0.22%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
58% less funds holding
Funds holding: 43 → 18 (-25)
92% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$70.5K |
| 2 |
Morgan Stanley
New York
|
+$36.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$27.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$5.42K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$225K |
| 2 |
Renaissance Technologies
New York
|
-$170K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$153K |
| 4 |
Millennium Management
New York
|
-$150K |
| 5 |
E
Ergoteles
New York
|
-$142K |
AVTX Hedge Fund Activity: Q3 2022 in Review
18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2022, worth a combined $18.4M — up 68% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AVTX and 2 opened new positions — a net loss of 24 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $70.5K. The largest seller was Opaleye Management, exiting entirely with an estimated $225K sold.
- 18 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2022, down from 43 in Q2 2022.
- Funds reported $18.4M of Avalo Therapeutics stock for Q3 2022, up 68% quarter-over-quarter.
- 2 funds opened new Avalo Therapeutics positions in Q3 2022 and 26 closed out, a net change of -24 holders.
- The largest Avalo Therapeutics buyer in Q3 2022 was Assenagon Asset Management, an estimated $70.5K added.
- The largest Avalo Therapeutics seller in Q3 2022 was Opaleye Management, an estimated $225K sold.
Based on aggregated 13F filings for Q3 2022.